How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,712 results for

Thromboembolic Disease in Pregnancy

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Risk of Venous Thromboembolism Among Users of Drospirenone-Containing Oral Contraceptive Pills

, this risk is still very low and is much lower than the risk of venous thromboembolism during pregnancy and the immediate postpartum period. When prescribing any oral contraceptive, clinicians should consider a woman’s risk factors for venous thromboembolism and refer to the U.S. Medical Eligibility Criteria for Contraceptive Use issued by the Centers for Disease Control and Prevention. Patient education materials, including product labeling, should place information regarding oral contraceptive use (...) and venous thromboembolism risks in context by also providing information about overall venous thromboembolism risks and venous thromboembolism risks during pregnancy and the postpartum period. Decisions regarding choice of oral contraceptive should be left to clinicians and their patients, taking into account the possible minimally increased risk of venous thromboembolism, patient preference, and available alternatives. Combined oral contraceptives (OCs) that contain drospirenone have been widely used

2012 American College of Obstetricians and Gynecologists

82. Thromboprophylaxis reduces venous thromboembolism rate in ambulatory patients immobilised in above knee plaster cast.

and Critical Care Institution: Lancashire Teaching Hospitals NHS Trust Date Submitted: 5th July 2011 Date Completed: 13th June 2012 Last Modified: 13th June 2012 Status: Green (complete) Three Part Question In [patients with lower extremity injury requiring temporary immobilisation with above knee plaster of paris] does [prophylactic anticoagulation with LMWH] reduce the risk of [venous thromboembolic disease within the next three months] Clinical Scenario You see a 27 year old male who has ruptured his (...) Thromboprophylaxis reduces venous thromboembolism rate in ambulatory patients immobilised in above knee plaster cast. BestBets: Thromboprophylaxis reduces venous thromboembolism rate in ambulatory patients immobilised in above knee plaster cast. Thromboprophylaxis reduces venous thromboembolism rate in ambulatory patients immobilised in above knee plaster cast. Report By: Catherine Roberts - SpR in Emergency Medicine & Critical Care Search checked by Daniel Horner - StR in Emergency Medicine

2012 BestBETS

83. Haemorrhages and Thromboembolic Venous Disease of the Postpartum

Thromboembolism Venous Thromboembolism Postpartum Hemorrhage Pathologic Processes Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Obstetric Labor Complications Pregnancy Complications Puerperal Disorders Uterine Hemorrhage (...) Haemorrhages and Thromboembolic Venous Disease of the Postpartum Haemorrhages and Thromboembolic Venous Disease of the Postpartum - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Haemorrhages

2015 Clinical Trials

84. A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. (PubMed)

-language publications about adult patients with rheumatologic inflammatory diseases and venous thromboembolisms (VTEs). Data regarding rates of DVTs and PEs were extracted. Using random-effects models, pooled estimates for VTEs in individual and pooled diseases were compared with matched populations where possible. Studies were excluded if VTEs were described in the setting of pregnancy, postoperative outcomes or solely antiphospholipid antibody syndrome.Most of the 5,206 studies were excluded because (...) A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. We performed a meta-analysis to investigate the risk of deep vein thrombosis (DVT) and/or pulmonary embolisms (PEs) in patients with inflammatory arthritis, vasculitis and connective tissue diseases (CTDs) (systemic lupus erythematosus (SLE), Sjögren's syndrome, inflammatory myositis and systemic sclerosis (SSc)).PubMed, Embase, the Cochrane databases and MEDLINE were searched to identify full-text English

Full Text available with Trip Pro

2015 Arthritis research & therapy

85. Management of Beta Thalassaemia in Pregnancy

for liver iron, cardiac iron and fructosamine ? thalassaemia intermedia pregnancy outcomes, especially indications for transfusion, management of maternal anaemia in nontransfused patients and FGR ? compliance with prophylaxis against venous thromboembolic disease in women who have undergone splenectomy. Evidence level 4 Evidence level 4 Evidence level 1++ D PReferences 1. Ryan K, Bain BJ, Worthington D, James J, Plews D, Mason A, et al.; British Committee for Standards in Haemotology. Significant (...) T. Outcomes of pregnancies complicated by beta-thalassemia/hemoglobin E disease. Int J Gynaecol Obstet 2009;104:203–5. 46. Bajoria R, Chatterjee R. Current perspectives of fertility and pregnancy in thalassemia. Hemoglobin 2009;33 Suppl 1:S131–5. 47. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood 2002;99:36–43. 48. Cappellini MD, Poggiali E, Taher AT, Musallam KM. Hypercoagulability in ß-thalassemia: a status quo. Expert Rev Hematol 2012;5:505–11. 49. Anderson LJ

2014 Royal College of Obstetricians and Gynaecologists

86. Contraception after pregnancy. (PubMed)

that this may not necessary, at least for healthy women <35 years old. Most contraceptive methods can be used after pregnancy regardless of the outcome. Because of an increased risk of venous thromboembolism associated with estrogen-containing contraceptives initiation of these methods should be delayed until 6 weeks after childbirth. More research is required to settle the questions over the use of combined hormonal contraception during breastfeeding, the use of injectable progestin-only contraceptives (...) before 6 weeks after childbirth and use of both hormonal and intrauterine contraception after gestational trophoblastic disease. The potential impact on the risk of ectopic pregnancy of certain contraceptive methods often confuses healthcare providers. The challenges involved in providing effective, seamless service provision of contraception after pregnancy are numerous, even in industrialised countries. Nevertheless, the clear benefits demonstrate that it is worth the effort. This article

2019 Acta Obstetricia et Gynecologica Scandinavica

87. CT for Pulmonary Thromboembolic Disease

CT for Pulmonary Thromboembolic Disease CT for Pulmonary Thromboembolic Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. CT for Pulmonary Thromboembolic Disease (CT for PE) The safety and scientific (...) Details Study Description Go to Brief Summary: Examine the feasibility and efficacy of individually optimized uniform contrast enhancement in CT pulmonary angiography (CTPA) for the diagnosis of pulmonary thromboembolic disease. Condition or disease Pulmonary Embolism Detailed Description: Patient characteristics, qualitative image quality scores, and quantitative contrast enhancement and CNR will be described using mean values and standard deviations for continuous variables, and frequencies

2014 Clinical Trials

88. Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs

Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs (MYELAXAT) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02066454 Recruitment Status : Unknown Verified

2014 Clinical Trials

89. SToP: Venous Thromboembolism Screening in the Trauma Population

. The study will compare the two groups with regard to deep vein thrombosis, pulmonary embolism, and major and clinically relevant bleeding episode rates, both during the index hospitalization and at 90 days post-discharge. Condition or disease Intervention/treatment Phase Venous Thromboembolism Deep Vein Thrombosis Trauma, Multiple Other: Duplex ultrasound surveillance Other: No ultrasound surveillance Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (...) Product: No Keywords provided by Intermountain Health Care, Inc.: duplex ultrasound trauma venous thromboembolism prevention Additional relevant MeSH terms: Layout table for MeSH terms Wounds and Injuries Thrombosis Thromboembolism Venous Thromboembolism Venous Thrombosis Multiple Trauma Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases

2016 Clinical Trials

90. Anti Xa Activity in Cancer Patients Receiving Low-molecular-weight Heparin for Venous Thromboembolism

-Xa activity on the occurrence of thromboembolic recurrence in cancer patients treated with LMWH for VTE. Condition or disease Neoplasms Venous Thromboembolism Study Design Go to Layout table for study information Study Type : Observational Actual Enrollment : 370 participants Observational Model: Case-Control Time Perspective: Prospective Official Title: Anti Xa Activity in Cancer Patients Receiving Low-molecular-weight Heparin for Venous Thromboembolism Actual Study Start Date : August 2011 (...) Criteria: Case: Being affiliated to a social security scheme Having an active solid or hematological cancer (myeloma or lymphoma), histologically or cytologically confirmed, for which the active state will be defined by the existence of a tumoral active disease or an incomplete tumoral resection or the persistence of high tumor markers after complete resection of the tumor. The venous thromboembolism disease has to be: A deep vein thrombosis of lower extremity (proximal or distal) confirmed by the lack

2016 Clinical Trials

91. Bosentan in Myocardium Metabolism and Perfusion Measured by 18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) and Rubidium-82 (82Rb) Positron Emission Tomography/Computed Tomography (PET/CTs) on Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmo

Bosentan in Myocardium Metabolism and Perfusion Measured by 18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) and Rubidium-82 (82Rb) Positron Emission Tomography/Computed Tomography (PET/CTs) on Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmo Bosentan in Myocardium Metabolism and Perfusion Measured by 18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) and Rubidium-82 (82Rb) Positron Emission Tomography/Computed Tomography (PET/CTs) on Pulmonary Arterial Hypertension (PAH) or Chronic (...) Thromboembolic Pulmonary Hypertension (CTEPH) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Bosentan in Myocardium Metabolism and Perfusion Measured by 18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) and Rubidium-82 (82Rb

2016 Clinical Trials

92. Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients

as compared with guideline recommended subcutaneous heparin. Antifactor Xa assay, a laboratory test to measure the anticoagulant activity of heparin, or the ability of heparin to thin the blood, will be used to demonstrate that Intravenous administration is more effective. Condition or disease Intervention/treatment Phase Venous Thromboembolism Drug: intravenous continuous infusion of heparin (IV UFH) Drug: Subcutaneous Heparin Not Applicable Study Design Go to Layout table for study information Study (...) information Responsible Party: New York University School of Medicine ClinicalTrials.gov Identifier: Other Study ID Numbers: 15-01051 First Posted: March 14, 2016 Last Update Posted: April 27, 2017 Last Verified: April 2017 Keywords provided by New York University School of Medicine: heparin Additional relevant MeSH terms: Layout table for MeSH terms Critical Illness Thromboembolism Venous Thromboembolism Disease Attributes Pathologic Processes Embolism and Thrombosis Vascular Diseases Cardiovascular

2016 Clinical Trials

93. Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants

. FDA-regulated Device Product: No Keywords provided by Centre Hospitalier Universitaire de Saint Etienne: Renal insufficiency Direct oral anticoagulants (DOA) Deep Vein Thrombosis (DVT) Pulmonary Embolism (PE) Venous Thromboembolism (VTE) Heparins Additional relevant MeSH terms: Layout table for MeSH terms Thromboembolism Venous Thromboembolism Renal Insufficiency Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Kidney Diseases Urologic Diseases Heparin Calcium heparin Rivaroxaban (...) Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2016 Clinical Trials

94. Tumor-educated Platelets in Venous Thromboembolism

for cancer detection, but its clinical utility in patients with unprovoked VTE is unknown. The objective of the present study is to evaluate the diagnostic accuracy of platelet RNA profiling in detecting occult cancer in patients with unprovoked venous thromboembolism. Secondary objectives include evaluation of other biomarkers for cancer, prediction of bleeding, and prediction of recurrent VTE. Condition or disease Neoplasms Venous Thromboembolism Study Design Go to Layout table for study information (...) (of note: suspected but unconfirmed cancer at diagnosis of VTE is allowed); trauma or fracture of the leg, surgical procedures, general anesthesia, or immobilization greater than 3 days within previous 3 months; previous unprovoked venous thromboembolism; known hereditary or acquired thrombophilia; current pregnancy or puerperium (up to 3 months postpartum); current estrogen therapy. Greater than 10 days after VTE diagnosis; Inability for blood withdrawal at baseline; Inability or refusal to provide

2016 Clinical Trials

95. Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma

methods [diaphragm, condoms, spermicides]) to avoid pregnancy for the entire study Any prior venous thromboembolism Contraindication to anticoagulant therapy Conditions for which serious bleeding may occur including: Current or within last 6 months: intracranial bleeding, intraocular bleeding, gastrointestinal bleeding, endoscopically documented ulcer disease Current or within last month: head trauma or other major trauma, major surgery Current or within last 2 weeks: stroke, neurosurgical procedure (...) : Gregory Piazza Collaborator: Bristol-Myers Squibb Information provided by (Responsible Party): Gregory Piazza, Brigham and Women's Hospital Study Details Study Description Go to Brief Summary: Patients living with multiple myeloma (MM) have an increased risk of venous thromboembolism (VTE) due to the disease itself and the use of targeted therapies, including immunomodulatory drugs (IMiDs). Prevention of VTE has become a major management challenge during MM treatment. There is a paucity of data

2016 Clinical Trials

96. IgG Dependent Monocyte Activation in Proximal Venous Thromboembolism

with a chronic history of proximal venous thromboembolism and new patients coming in for a checkup. Note that these patients may or may not have a history of placental vascular disease. Intervention: Blood sampling Biological: Blood sampling Venous blood will be sampled for laboratory analyses (see outcomes). Women with >1 healthy pregnancy This populations is composed of healthy, female, adult volunteers (<50 years in age) that have had at least 1 healthy pregnancy. Intervention: Blood sampling Biological (...) between patients with a chronic history of proximal venous thromboembolism and new patients coming in for a checkup. Note that these patients may or may not have a history of placental vascular disease. Healthy volunteer population description: This populations is composed of healthy, female, adult volunteers (<50 years in age) that have had at least 1 healthy pregnancy. Criteria Inclusion Criteria for patients: The patient has given her informed and signed consent The patient must be insured

2016 Clinical Trials

97. Thromboembolism Risk Factors

: Initial Venous Thromboembolism by chronicity Major transient risks Hospitalization Plaster cast immobilization Surgery Minor transient risks Prolonged travel >2 hours (risk increases 18% for every 2 hours traveled) Pregnancy s or other hormone therapy Persistent risks Collagen vascular disease Cancer Myeloproliferative disorders VI. Risk Factors: Recurrent Thromboembolism after stopping Anticoagulants (Relative Risk) Metastatic cancer (6-9) Factor VIII >200 IU/dl (6) Non-metastatic Cancer (3) (2.5 (...) cause found in up to one third of DVT cases Prior (DVT) Medications Increased or Pregnancy (Nolvadex) Phenothiazines Major Recent Surgery (e.g. ) Cancer Consider evaluation for occult cancer in DVT Polycythemia History of thromboembolic disease Deep Venous Thrombosis Type A Blood IX. Risk Factors: Intimal damage Local Surgery (Especially ral and Orthopedic Surgery) ral anesthesia is an independent risk factor Consider Penetrating vessel injury Especially femoral X. References Images: Related links

2018 FP Notebook

98. Anticoagulation in Thromboembolism

Anticoagulation in Thromboembolism Anticoagulation in Thromboembolism Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Anticoagulation (...) with (as opposed to starting on day 1-2 as with older protocols) Delay in past has been due to initial prothrombotic effect of However appears to counter this effect even early in course and s are contraindicated in pregnancy, severe liver disease, breakthrough VTE, some cancers See Continue in these cases Initial Dosing See for further dosing information Age <65 years: Start 10 mg daily Dose of 10 mg start was therapeutic 1.4 days earlier Age >65 years: Start 5 mg daily Age >75 years: Start 2.5 mg daily Check

2018 FP Notebook

99. Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

in pediatric subjects with confirmed VTE. Condition or disease Intervention/treatment Phase Venous Thromboembolism (VTE) Pulmonary Embolism Deep Vein Thrombosis (DVT) Drug: Edoxaban Drug: Standard of Care Phase 3 Detailed Description: The objective is to demonstrate the non-inferiority of edoxaban to standard of care (SOC; including low molecular weight heparin (LMWH), vitamin K antagonist (VKA), or synthetic pentasaccharide (SP) Xa inhibitors) in the treatment and secondary prevention of VTE in pediatric (...) relevant MeSH terms: Layout table for MeSH terms Thrombosis Thromboembolism Embolism Venous Thromboembolism Pulmonary Embolism Venous Thrombosis Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases Heparin Edoxaban Fondaparinux Anticoagulants Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Factor Xa Inhibitors Antithrombins Serine Proteinase Inhibitors Protease Inhibitors Enzyme Inhibitors

2016 Clinical Trials

100. Inflammation as a cause of venous thromboembolism. (PubMed)

inflammation-related conditions including aging, autoimmune disease, cancer, cardiovascular diseases, hormone replacement therapy, infectious diseases, metabolic diseases, overweight or obesity, pregnancy or postpartum, respiratory diseases, and trauma have been associated with an increased risk of VTE. At this moment, despite their theoretical potential, to achieve the implementation of the inflammation-related laboratory tests in practice is a long task and future studies with larger sample sizes (...) Inflammation as a cause of venous thromboembolism. Inflammatory markers are highly amenable to appraise and adjust and could already serve as a diagnostic indicator and also as a predictor of prognosis over the management of many health problems. Inflammation is implicated in venous thromboembolism (VTE). However there is still an intense curiosity about whether it is a cause or only a consequence of the thromboembolic process. The more likely scenario is that some inflammatory mediators

2016 Critical reviews in oncology/hematology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>